flow trial semaglutide kidney outcomes 2024 nejm hazard ratio clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Effects of Once-Weekly Semaglutide on

What dose will I start on

Understanding GLP-1 medications GLP-1 (glucagon-like peptide-1) receptor agonists, like semaglutide (the active ingredient in Ozempic and Wegovy), act like the GLP-1 hormone thats naturally made in your body

Clinical trials evaluating semaglutide for weight management, including the pivotal STEP (Semaglutide Treatment Effect in People with obesity) programme published in the New England Journal of Medicine (2021), did not demonstrate a statistically significant increase in UTI incidence compared to placebo groups

It has been investigated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) program, which showed significant reductions in glycated hemoglobin (A1c) and body weight (BW) compared to placebo or other treatments [7,8,9,10,11,12,13,14]

The FDA approved Zepbound for people with obesity and those who are overweight and have at least one health condition linked to their weight, such as high blood pressure, Type 2 diabetes or high cholesterol, according to an FDA press release

Alongside protein, fibre intake often drops, and some people experience bloating, nausea or constipation, particularly in the early weeks